A new study shows there is little to no clinical benefit in reducing TNFi treatment dosages for patients with axial spondyloarthritis (axSpA).
A comprehensive review of published studies on gut microbiota, immunity and arthritis suggests that having a microbial imbalance may precede the development of spondyloarthritides and osteoarthritis.
Prime-boost vaccination is more immunogenic than single pneumococcal vaccine in conventional disease-modifying antirheumatic drug (cDMARD) or abatacept-treated patients, but not in patients on rituximab, say researchers writing in Arthritis Research & Therapy.
Adding methotrexate to adalimumab (Humira, AbbVie) in axial spondyloarthritis was associated with reduced immunogenicity, and prolonged co-medication was associated with long-term maintenance of adalimumab, say researchers recently writing in RMD Open: Rheumatic & Musculoskeletal Diseases.
A study of 312,081 pregnant women with rheumatoid arthritis, spondyloarthritis or no inflammatory arthritis, finds that women with rheumatoid arthritis are more likely to have pregnancy complications.
Long-term use of tumor necrosis factor inhibitors (TNFi) may show radiographic progression benefit in axial spondyloarthritis, say researchers recently writing in Arthritis & Rheumatology.
The practice of systematically tapering biological disease modifying antirheumatic drugs (bDMARDs) in all patients with inflammatory arthritis who have reached a certain disease activity target may not be supported by current evidence, according to a review published recently in Autoimmunity Reviews
The internationally recommended Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cutoff of four and above may not be applicable when initiating treatment with the tumor necrosis factor alpha inhibitor (TNFi) golimumab (Simponi, Janssen), say researchers recently writing in The Journal of Rheumatology.
Turkish researchers are reporting the results of small study that shows too much vitamin D may be associated with the severity of in disease ankylosing spondylitis patients. Learn more about this and other recent findings from spondylarthritis research in today's news roundup.
In patients with ankylosing spondylitis receiving treatment with non‐steroidal anti‐inflammatory drugs (NSAIDs), timely therapeutic strategies should be implemented in order to manage gastrointestinal risk, say researchers recently writing in the International Journal of Rheumatic Disease.